Completed PHASE2 INTERVENTIONAL 2-arm NCT01297491

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer (BASALT-1)

An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway

Sponsor: Novartis Pharmaceuticals

Conditions Non-small Cell Lung Cancer

Interventions BKM120

Updated 8 times since 2017 Last updated: Mar 10, 2016 Started: May 31, 2011 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-small Cell Lung Cancer and is currently completed. Novartis Pharmaceuticals leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

*see Various Departments*, United States , Alicante, Spain , Altunizade, Turkey (Türkiye) , Atlanta, United States , Aurora, United States , Avellino, Italy , Bangkok, Thailand , Barcelona, Spain , Barretos, Brazil , Berlin, Germany and 77 more locations